Biotechnology News 24 December 2025

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235

30 December 2025

Biotechnology·Financial News·Investing·Market Trends·Stock Market

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a

30 December 2025

Biotechnology·FDA Approvals·Investment Analysis·Pharmaceutical News·Stock Market

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML)

30 December 2025

Biotechnology·Clinical Trials·Investment News·Pharma Industry·Stock Market

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment.

30 December 2025

Biotechnology·FDA Approvals·Investment Insights·Pharmaceutical Industry·Stock Market News

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead

30 December 2025

Biotechnology·Clinical Trials·Pharma News·Stock Market

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive

30 December 2025

Biotechnology·Clinical Trials·Investment News·Market Analysis

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 3:41 a.m. ET — Market closed (weekend). Regencell Bioscience Holdings Limited (NASDAQ: RGC) heads into the weekend with traders focused on one thing: volatility. RGC stock finished the last regular session (Friday) sharply lower, while

28 December 2025

Biotechnology·Financial Analysis·Investment News·Nasdaq·Stock Market

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

NEW YORK, Dec. 27, 2025, 8:12 p.m. ET — Market closed Moderna, Inc. (NASDAQ: MRNA) stock heads into the weekend with investors parsing a mix of technical read-throughs, biotech-sector screens, and diverging Wall Street targets after a sharp pullback in

28 December 2025

Analyst Insights·Biotechnology·Investment News·Market Trends·Stock Market

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech

27 December 2025

Biotechnology·Investments·Stock Market

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s That timing matters today because Zai Lab Limited (NASDAQ:

26 December 2025

Biotechnology·Investment Analysis·Pharma News·Stock Market

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session (standard hours are 9:30 a.m. to 4:00 p.m. ET). Nasdaq Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is

26 December 2025

Biotechnology·Financial Updates·Investment·Pharmaceutical News·Stock Market

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly and Company (NYSE: LLY) wrapped up a holiday-shortened Christmas Eve session with a modest gain — and then drifted slightly lower in thin after-hours trading as investors digested a policy-heavy news cycle around GLP‑1 obesity medicines. With U.S.

24 December 2025

After Hours Trading·Biotechnology·Market Analysis·Pharmaceutical News·Stock Market

Biotechnology News 24 December 2025 - 30 December 2025